FDA Approves Koselugo for Pediatric Neurofibromatosis Type 1

TUESDAY, April 14, 2020 -- Koselugo (selumetinib) has received the first approval for treatment of neurofibromatosis type 1 (NF1) in children ages 2 years and older, the U.S. Food and Drug Administration announced Friday. Approved specifically for...
Source: Drugs.com - Daily MedNews - Category: General Medicine Source Type: news